Women of childbearing age using tirzepatide should be advised to switch to a non-oral contraceptive method or add a barrier method." Specialist Pharmacy Service (SPS) For patients on tirzepatide, healthcare providers recommend switching to non-oral contraceptives or adding a barrier method (like condoms) for four weeks after starting the drug and four weeks after each dose increase
When the industry's own trade association directs pharmacists to refuse, the legal position is settled
No pharmaceutical company has funded the human clinical trials required for FDA approval
A phase II study result showed that administering a high dose of survodutide, up to 1.8 mg twice weekly, resulted in over 50% of T2D participants achieving more than 5% body weight reduction, and over 25% experiencing a weight loss exceeding 10% [111]
Doubling the dose doesn't compensate for the gap and increases the risk of methionine overload
Research on growth hormone replacement shows that when GH levels are restored gently and monitored, the therapy is well tolerated with a low incidence of complications